Investigates outcome of systemic tumor treatment using TLR7 ligands, indicating enhanced efficacy with receptor sensitivity considerations.
Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Hotz et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: